Featured Studies Results
High Dose Testosterone Treatment for People with Metastatic Prostate Cancer and an ATM, CDK12 or CHEK2 Mutation
https://www.facingourrisk.org/research-clinical-trials/study/294 /high-dose-testosterone-treatment-for-people-with-metastatic-prostate-cancer-and-an-atm-cdk12-or-chek2mutation
Clinicaltrials.gov identifier:
NCT05011383 (https://clinicaltrials.gov/show/NCT05011383)
Treatment
People who have metastatic castration-resistant prostate cancer with an ATM, CDK12, or CHEK2 mutation
Screening Study for Men at High Genetic Risk for Prostate Cancer
https://www.facingourrisk.org/research-clinical-trials/study/72 /men-at-high-genetic-risk-for-prostate-cancer
Clinicaltrials.gov identifier:
NCT03805919 (https://clinicaltrials.gov/show/NCT03805919)
Prevention
Prostate screening with MRI for men with Lynch syndrome (MLH1, MSH2, MSH6, PMS2, EPCAM) or a BRCA1, BRCA2, HOXB13, ATM, NBN, TP53, BRIP1, CHEK2, PALB2, RAD51C, RAD51D, or other mutation
Carboplatin Chemotherapy before Surgery for Patients with High-Risk Prostate Cancer and an Inherited BRCA1 or BRCA2 Gene Mutation
https://www.facingourrisk.org/research-clinical-trials/study/286 /swog-s2210-carboplatin-chemotherapy-before-surgery-for-patients-with-high-risk-prostate-cancer-and-an-inherited-brca1-or-brca2-gene-mutation
Clinicaltrials.gov identifier:
NCT05806515 (https://clinicaltrials.gov/show/NCT05806515)
Treatment
Treatment before surgery for people with high-risk prostate cancer and an inherited BRCA1 or BRCA2 gene mutation
Validating a Blood Test for Early Ovarian Cancer Detection in High-risk Women and Families: MicroRNA Detection Study (MiDE)
https://www.facingourrisk.org/research-clinical-trials/study/138 /validating-a-blood-test-for-early-ovarian-cancer-detection-in-high-risk-women-and-families
Prevention
Screening study for women with a BRCA1, BRCA2, BRIP1, PALB2, RAD51C, RAD51D, PMS2, MLH1, MSH2, MSH6, or EPCAM mutation
Using ctDNA Blood Test for Earlier Detection and Treatment of Recurrence or Spread after Treatment for Stage 3 Colon Cancer
https://www.facingourrisk.org/research-clinical-trials/study/283 /using-ctdna-for-earlier-detection-and-treatment-of-recurrence-or-spread-after-treatment-for-stage-3-colon-cancer
Clinicaltrials.gov identifier:
NCT03803553 (https://clinicaltrials.gov/show/NCT03803553)
Treatment
Monitoring and treatment study for people who completed treatment for stage 3 colon cancer
Comparing a Combination of Drugs for Treatment of HER2-positive Colorectal Cancer as First Line Treatment in the Metastatic Setting
https://www.facingourrisk.org/research-clinical-trials/study/274 /treatment-of-her2-positive-colorectal-cancer-as-first-line-treatment-in-the-metastatic-setting
Clinicaltrials.gov identifier:
NCT05253651 (https://clinicaltrials.gov/show/NCT05253651)
Treatment
People with HER2-positive colorectal cancer who have not yet received treatment in the metastatic setting
Study of Colorectal Cancer and Genetics in Hispanic and Latino People (ENLACE Study)
https://www.facingourrisk.org/research-clinical-trials/study/276 /study-of-colorectal-cancer-and-genetics-in-hispanic-and-latino-people-enlace-study
Treatment
Hispanic and Latino people diagnosed with colorectal cancer
Pancreatic Cancer Early Detection for People at High Risk
https://www.facingourrisk.org/research-clinical-trials/study/227 /pancreatic-cancer-early-detection-for-people-at-high-risk
Clinicaltrials.gov identifier:
NCT04970056 (https://clinicaltrials.gov/show/NCT04970056)
Prevention
Registry and biobank for high risk people undergoing pancreatic cancer screening
Collecting Blood and Stool Samples to Detect Colorectal Cancer or Precancerous Polyps in Lynch Syndrome Patients (CORAL Study)
https://www.facingourrisk.org/research-clinical-trials/study/256 /early-detection-of-colorectal-cancer-for-people-with-lynch-syndrome
Clinicaltrials.gov identifier:
NCT05410977 (https://clinicaltrials.gov/show/NCT05410977)
Prevention
People with Lynch Syndrome at risk for colon cancer
Study of the PARP inhibitor AZD9574 Alone and Combined with Other Cancer Medicines to Treat People with Advanced Solid Cancers (CERTIS1 Study)
https://www.facingourrisk.org/research-clinical-trials/study/282 /study-of-the-parp-inhibitor-azd9574-alone-and-combined-with-other-cancer-medicines-to-treat-people-with-advanced-solid-cancers-certis1-study
Clinicaltrials.gov identifier:
NCT05417594 (https://clinicaltrials.gov/show/NCT05417594)
Treatment
Treatment study for people with advanced breast, ovarian, pancreatic or prostate cancer or gliomas
The WISDOM Study: Women Informed to Screen Depending on Measures of Risk
https://www.facingourrisk.org/research-clinical-trials/study/45 /wisdom-study
Clinicaltrials.gov identifier:
NCT02620852 (https://clinicaltrials.gov/show/NCT02620852)
Prevention
Genetic testing and breast cancer screening
MRI Screening in Men at High Risk of Developing Prostate Cancer
https://www.facingourrisk.org/research-clinical-trials/study/260 /screening-in-men-at-high-risk-of-developing-prostate-cancer
Clinicaltrials.gov identifier:
NCT05608694 (https://clinicaltrials.gov/show/NCT05608694)
Prevention
Screening using MRI for men at risk of developing prostate cancer
Studying People and Families Affected by Li-Fraumeni Syndrome (TP53 Mutation )
https://www.facingourrisk.org/research-clinical-trials/study/267 /observing-people-who-have-li-fraumeni-syndrome-tp53-genetic-mutation
Clinicaltrials.gov identifier:
NCT01443468 (https://clinicaltrials.gov/show/NCT01443468)
Surveys, Registries, Interviews
Registry for people with Li-Fraumeni syndrome (LFS) or from LFS families
A Surveillance Program for Women at High Risk for Breast Cancer (CAPSBRACA)
https://www.facingourrisk.org/research-clinical-trials/study/271 /a-surveillance-program-for-women-at-high-risk-for-breast-cancer-capsbraca
Clinicaltrials.gov identifier:
NCT03729115 (https://clinicaltrials.gov/show/NCT03729115)
Surveys, Registries, Interviews
Screening study for women at risk for breast cancer due to an inherited mutation or other risk factor
Risk Reducing Salpingectomy With Delayed Oophorectomy as an Alternative to Risk- Reducing Salpingo-oophorectomy in High-Risk Women
https://www.facingourrisk.org/research-clinical-trials/study/205 /risk-reducing-salpingectomy-with-delayed-oophorectomy-as-an-alternative-to-risk-reducing-salpingo-oophorectomy-in-high-risk-women
Clinicaltrials.gov identifier:
NCT05287451 (https://clinicaltrials.gov/show/NCT05287451)
Prevention
Prevention study for women at high risk for ovarian cancer
A Study of Targeted Therapies for Patients With Recurrent Endometrial Cancer
https://www.facingourrisk.org/research-clinical-trials/study/245 /a-study-of-different-targeted-therapies-for-patients-with-recurrent-or-persistent-endometrial-cancer
Clinicaltrials.gov identifier:
NCT04486352 (https://clinicaltrials.gov/show/NCT04486352)
Treatment
Phase 2 treatment study for recurrent endometrial cancer
A Study Comparing Two Anti-inflammatory Medications Naproxen or Aspirin for Cancer Prevention in Lynch Syndrome
https://www.facingourrisk.org/research-clinical-trials/study/281 /studying-the-use-of-naproxen-and-aspirin-for-cancer-prevention-in-people-with-lynch-syndrome
Clinicaltrials.gov identifier:
NCT05411718 (https://clinicaltrials.gov/show/NCT05411718)
Prevention
Prevention study for people with Lynch syndrome
Kindred Study
https://www.facingourrisk.org/research-clinical-trials/study/255 /kindred
Surveys, Registries, Interviews
Interviews with African American people who tested positive for a genetic mutation
About FORCE
FORCE is a national nonprofit organization, established in 1999. Our mission is to improve the lives of individuals and families affected by adult hereditary cancers.